Weight ManagementAlso known as: Adlyxin, Lyxumia, AVE0010
Lixisenatide
Once-daily GLP-1 receptor agonist (Adlyxin/Lyxumia) — an exendin-4 derivative with strong post-prandial glucose lowering. Also available as Soliqua (combined with insulin glargine).
Half-Life
~3 hours
Dose Range
10-20 mcg/day
Frequency
1× daily
Vial Sizes
0.05 mg, 0.1 mg
Mechanism of Action
Modified exendin-4 with C-terminal truncation and six-lysine tail for improved stability. Short-acting GLP-1R agonist with pronounced gastric emptying delay, producing superior post-prandial glucose reduction compared to longer-acting GLP-1 agonists.
Source: PMID: 23404299 (GetGoal trials)
Dosing Protocol
| Typical Dose | 10-20 mcg/day |
| Frequency | 1× daily |
| Half-Life | ~3 hours |
| Common Vial Sizes | 0.05 mg, 0.1 mg |
Dosing Quick Reference
Lixisenatide— Dosing Guide
Dose Range
10-20 mcg/day
Half-Life
~3 hours
Frequency
1× daily
Route
Oral
0.05 mg vial0.1 mg vial
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code